Clinical evaluation of somatostatin use in pancreatic resections: Clinical efficacy or limited benefit?
Authors:
- Erik Dunki-JacobsEDErik Dunki-Jacobs
- Glenda G. CallenderGCGlenda G. Callender
- Nick BurnettNBNick Burnett
- Charles R. ScogginsCSCharles R. Scoggins
- Kelly M. McMastersKMKelly M. McMasters
- Robert C.G. MartinRobert C.G. Martin
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Cancer statistics, 2013CA: A Cancer Journal for Clinicians, 2013
- Management of complications following pancreatic resection: An evidence‐based approachJournal of Surgical Oncology, 2012
- Comparison of outcomes and costs between laparoscopic distal pancreatectomy and open resection at a single centerSurgical Endoscopy, 2011
- Meta-analysis of randomized controlled trials on the effectiveness of somatostatin analogues for pancreatic surgery: a Cochrane reviewHPB, 2010
- Pancreatic fistula after pancreatectomy: Evolving definitions, preventive strategies and modern managementWorld Journal of Gastroenterology, 2008
- Pancreatic resectional surgery: An evidence-based perspectiveJournal of Cancer Research and Therapeutics, 2008
- One Thousand Consecutive PancreaticoduodenectomiesAnnals of Surgery, 2006
- Meta-analysis of the value of somatostatin and its analogues in reducing complications associated with pancreatic surgeryBritish Journal of Surgery, 2005
- Randomized controlled multicentre trial of somatostatin infusion after pancreaticoduodenectomyBritish Journal of Surgery, 2001
- SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged actionLife Sciences, 1982